Expert Insights On Upstream Bioprocessing
-
How Advanced PAT Aids Quality By Digital Design In mRNA Manufacturing
5/15/2024
QbDD is an improvement over the QbD paradigm. Here, computational models are used to characterize, monitor, control, and improve manufacturing processes.
-
Evaluating, Validating, And Implementing NAT-Based Mycoplasma Detection Methods
5/3/2024
Regulatory authorities advocate using alternative adventitious agent tests, but adoption has been slow. Here’s how to validate an alternative mycoplasma detection assay.
-
Forum Notebook: Quick Takes From USP's mRNA Virtual Summit
5/1/2024
The United States Pharmacopeia held a forum in February to exchange ideas about analytical methodologies and release testing. Here's a recap of the event.
-
SUS, PAT, And Other Tech Advancing Upstream Bioprocessing
4/26/2024
As the sector grows, technology and techniques are becoming more sophisticated, including single-use systems, automation, and bioreactors.
-
NK Cell Therapies: How Artiva Biotherapeutics Leverages Its "Manufacturing First" Approach
4/24/2024
We caught up with Chris Horan, Artiva Biotherapeutics' CTO, to discuss natural killer cell therapies and Artiva’s experiences and strategies with its candidate, AlloNK.
-
Improving Governance And Compliance With Knowledge Management
4/23/2024
Knowledge management — it’s not just a soulless exercise. In the last part of his series, Hirsh helps bridge the gap between compliance and business needs.
-
Cell Counting Is Growing More Important Amid Advanced Therapy's Rise
4/12/2024
You can't improve what you don't measure. This discussion explores advances in cell counting technology and the growing number of ways it aids the biotech industry and beyond.
-
How Continuous Bioprocessing Is Shaping Modern Biopharma Manufacturing
3/28/2024
Continuous processing adoption so far has been slow; however, market research shows demand and capacity will grow significantly over the next four years.
-
How To Measure Cell Density In Real Time With Soft Sensors
3/21/2024
Soft sensors can enable real-time monitoring of key process variables, including viable cell density. Here's how one team at Takeda put them to use.
-
How Pharma 4.0 Can Unlock The Full Potential Of External Manufacturing
2/27/2024
To address today's challenges and other headwinds, pharma/biotech organizations and CMO/CDMO partners need to re-evaluate and improve externalized operating models. Consider further investing in digitalizing collaboration processes as part of operational excellence and digital transformation road map efforts.